Compare Stocks: RAPT, IOVA, KNSA, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$14.09 -0.4%	$10.94	$1.76 ▼ $15.37	$6.38B	0.76	16.63 million shs	7.75 million shs
KNSA Kiniksa Pharmaceuticals International	$76.73 -5.0%	$78.13	$35.20 ▼ $84.06	$5.99B	0.04	617,201 shs	575,399 shs
RAPT Rapt Therapeutics	$58.02	$57.90	$5.67 ▼ $58.02	$1.61B	0.49	4.25 million shs	N/A
RYTM Rhythm Pharmaceuticals	$89.27 -1.8%	$99.15	$74.50 ▼ $122.20	$6.12B	2.01	754,560 shs	536,875 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	0.00%	+3.45%	+30.46%	+182.36%	+555.35%
KNSA Kiniksa Pharmaceuticals International	0.00%	-2.37%	+1.84%	+22.10%	+97.25%
RAPT Rapt Therapeutics	0.00%	0.00%	0.00%	0.00%	+93.40%
RYTM Rhythm Pharmaceuticals	0.00%	+3.60%	-9.20%	-12.57%	-18.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$14.09 -0.4%	$10.94	$1.76 ▼ $15.37	$6.38B	0.76	16.63 million shs	7.75 million shs
KNSA Kiniksa Pharmaceuticals International	$76.73 -5.0%	$78.13	$35.20 ▼ $84.06	$5.99B	0.04	617,201 shs	575,399 shs
RAPT Rapt Therapeutics	$58.02	$57.90	$5.67 ▼ $58.02	$1.61B	0.49	4.25 million shs	N/A
RYTM Rhythm Pharmaceuticals	$89.27 -1.8%	$99.15	$74.50 ▼ $122.20	$6.12B	2.01	754,560 shs	536,875 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	0.00%	+3.45%	+30.46%	+182.36%	+555.35%
KNSA Kiniksa Pharmaceuticals International	0.00%	-2.37%	+1.84%	+22.10%	+97.25%
RAPT Rapt Therapeutics	0.00%	0.00%	0.00%	0.00%	+93.40%
RYTM Rhythm Pharmaceuticals	0.00%	+3.60%	-9.20%	-12.57%	-18.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IOVA Iovance Biotherapeutics	2.62	Moderate Buy	$13.20	-6.32% Downside
KNSA Kiniksa Pharmaceuticals International	2.89	Moderate Buy	$93.14	21.39% Upside
RAPT Rapt Therapeutics	2.00	Hold	$59.83	3.13% Upside
RYTM Rhythm Pharmaceuticals	2.77	Moderate Buy	$142.50	59.63% Upside

Current Analyst Ratings Breakdown

Latest RAPT, IOVA, KNSA, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	RYTM Rhythm Pharmaceuticals	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	RYTM Rhythm Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$146.00 ➝ $145.00
10/13/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$15.00 ➝ $18.00
10/12/2026	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$105.00 ➝ $130.00
10/8/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/8/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$155.00 ➝ $159.00
10/8/2026	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$6.00 ➝ $11.00
9/30/2026	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$14.00 ➝ $18.00
9/30/2026	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$87.00
9/29/2026	IOVA Iovance Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IOVA Iovance Biotherapeutics	$263.50M	24.22	N/A	N/A	$1.76 per share	8.01
KNSA Kiniksa Pharmaceuticals International	$677.56M	8.84	$0.79 per share	96.67	$7.44 per share	10.31
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	$11.51 per share	N/A
RYTM Rhythm Pharmaceuticals	$189.76M	32.24	N/A	N/A	$2.08 per share	42.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	79.10	37.07	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$11.06	N/A	N/A	N/A	N/A	-61.81%	-54.73%	N/A
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest RAPT, IOVA, KNSA, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	IOVA Iovance Biotherapeutics	-$0.0847	N/A	N/A	N/A	$115.53 million	N/A
11/3/2026	Q3 2026	RYTM Rhythm Pharmaceuticals	-$0.7101	N/A	N/A	N/A	$85.48 million	N/A
10/27/2026	Q3 2026	KNSA Kiniksa Pharmaceuticals International	$0.3710	N/A	N/A	N/A	$260.66 million	N/A
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IOVA Iovance Biotherapeutics	N/A	4.34	3.82
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
RAPT Rapt Therapeutics	N/A	12.04	12.04
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IOVA Iovance Biotherapeutics	77.03%
KNSA Kiniksa Pharmaceuticals International	53.95%
RAPT Rapt Therapeutics	99.09%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
IOVA Iovance Biotherapeutics	7.80%
KNSA Kiniksa Pharmaceuticals International	51.98%
RAPT Rapt Therapeutics	2.36%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable
KNSA Kiniksa Pharmaceuticals International	366	78.02 million	37.47 million	Optionable
RAPT Rapt Therapeutics	80	27.71 million	27.06 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable

RAPT, IOVA, KNSA, and RYTM Headlines

Recent News About These Companies

Rhythm Pharmaceuticals, Inc. (RYTM) - What Are Brokerages Saying About This Stock?

3 hours ago | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.50 According to Brokerages

3 hours ago | marketbeat.com

William Blair initiates coverage of Rhythm Pharmaceuticals at outperform

October 22 at 6:50 PM | msn.com

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

October 21, 2026 | globenewswire.com

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech with 67% Upside Potential

October 19, 2026 | directorstalkinterviews.com

176,882 Rhythm Pharmaceuticals, Inc. $RYTM Shares Purchased by Assenagon Asset Management S.A.

October 18, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Stock Sold by Aspiriant LLC

October 18, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Target Cut by JPMorgan Chase & Co.

October 17, 2026 | americanbankingnews.com

HC Wainwright Issues Optimistic Outlook for RYTM Earnings

October 16, 2026 | americanbankingnews.com

JPMorgan cuts target for Rhythm Pharmaceuticals stock to USD 145.00

October 15, 2026 | ad-hoc-news.deA

JPMorgan Chase & Co. Has Lowered Expectations for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

October 15, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. Announces Commercial Launch of IMCIVREE® (Setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

October 14, 2026 | marketscreener.comM

Rhythm launches IMCIVREE in Japan

October 14, 2026 | grafa.comG

Rhythm Launches Imcivree In Japan For Acquired Hypothalamic Obesity

October 14, 2026 | rttnews.com

HC Wainwright Has Positive Outlook for RYTM Q3 Earnings

October 14, 2026 | marketbeat.com

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

October 13, 2026 | globenewswire.com

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

October 13, 2026 | zacks.com

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Progress In Prader-Willi And Genetically Defined Obesity Therapies

October 13, 2026 | finance.yahoo.com

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 52.99% Upside Potential

October 12, 2026 | directorstalkinterviews.com

Rhythm's Imcivree Launch in Hypothalamic Obesity Encouraging, RBC Says

October 9, 2026 | finance.yahoo.com

RBC raises target for Rhythm Pharmaceuticals stock to USD 159

October 8, 2026 | ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPT, IOVA, KNSA, and RYTM Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

$14.09 -0.05 (-0.35%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$14.08 -0.02 (-0.11%)

As of 10/23/2026 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$76.73 -4.06 (-5.03%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$75.42 -1.31 (-1.71%)

As of 10/23/2026 07:48 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Rapt Therapeutics NASDAQ:RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Rhythm Pharmaceuticals NASDAQ:RYTM

$89.27 -1.63 (-1.79%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$89.20 -0.07 (-0.08%)

As of 10/23/2026 07:30 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RAPT, IOVA, KNSA, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RAPT, IOVA, KNSA, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RAPT, IOVA, KNSA, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPT, IOVA, KNSA, and RYTM Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Rapt Therapeutics NASDAQ:RAPT

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RAPT, IOVA, KNSA, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RAPT, IOVA, KNSA, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RAPT, IOVA, KNSA, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPT, IOVA, KNSA, and RYTM Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Rapt Therapeutics NASDAQ:RAPT

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools